Skip to main content
AAN.com

Abstract

Objective: To examine the relationship between stereologic estimates of AD-related pathology and severity of cognitive deficits in brain aging.
Background: Previous studies reported substantial contributions of neurofibrillary tangles (NFT), amyloid deposits, and neuronal loss to the development of dementia. However, the prediction of cognitive status based on nonstereologic quantification of these measures has led to conflicting results. Such studies have measured densities, rather than absolute numbers, and most do not take into account the potential interaction between the above pathologic hallmarks in a global multivariate analysis.
Methods: Clinicopathologic study in 22 elderly cases. Cognitive status assessed prospectively using the Mini-Mental State Examination (MMSE); stereologic assessment of NFT, unaffected neurons, and total amyloid volume in the CA1 field of the hippocampus, entorhinal cortex, and area 9. Statistical analysis was performed using both univariate and multivariate linear regression models.
Results: High total NFT counts but not amyloid volume were strongly associated with a lower number of unaffected neurons in all areas studied. A high proportion of variability in MMSE scores was explained by NFT and neuronal counts in the CA1 field (83% and 85.4%), entorhinal cortex (87.8% and 83.7%), and area 9 (87% and 79%); amyloid volume in the entorhinal cortex, but not in the CA1 field and area 9, accounted for 58.5% of MMSE variability. Multivariate analyses showed that total NFT counts in the entorhinal cortex and area 9 as well as neuron numbers in the CA1 field were the best predictors of MMSE score.
Conclusions: These new stereologic data indicate that neuronal pathology in hippocampal formation and frontal cortex closely reflects the progression of cognitive deficits in brain aging and AD. They also demonstrate that amyloid volume has no additional predictive value, in terms of clinicopathologic correlations, beyond its interaction with NFT.

Get full access to this article

View all available purchase options and get full access to this article.

Supplementary Material

File (e1.pdf)
File (e2.pdf)

References

1.
Lewis DA, Campbell MJ, Terry RD, Morrison JH. Laminar and regional distribution of neurofibrillary tangles and neuritic plaques in Alzheimer’s disease: a quantitative study of visual and auditory cortices. J Neurosci . 1987; 7: 1799–1808.
2.
Pearson RCA, Esiri MM, Hiorns RW, Wilcock GK, Powell TPS. Anatomical correlates of the distribution of the pathological changes in the neocortex in Alzheimer disease. Proc Natl Acad Sci USA . 1985; 82: 4531–4534.
3.
Rogers J, Morrison JH. Quantitative morphology and regional and laminar distributions of senile plaques in Alzheimer’s disease. J Neurosci . 1985; 5: 2801–2808.
4.
Morrison JH, Hof PR. Life and death of neurons in the aging brain. Science . 1997; 278: 412–419.
5.
Giannakopoulos P, Hof PR, Michel J-P, Guimon J, Bouras C. Cerebral cortex pathology in aging and Alzheimer’s disease: a quantitative survey of large hospital-based geriatric and psychiatric cohorts. Brain Res Rev . 1997; 25: 217–245.
6.
Hof PR, Bierer LM, Perl DP, et al. Evidence for early vulnerability of the medial and inferior aspects of the temporal lobe in an 82-year-old patient with preclinical signs of dementia—Regional and laminar distribution of neurofibrillary tangles and senile plaques. Arch Neurol . 1992; 49: 946–953.
7.
Vickers JC, Delacourte A, Morrison JH. Progressive transformation of the cytoskeleton associated with normal aging and Alzheimer’s disease. Brain Res . 1992; 594: 273–278.
8.
Bouras C, Hof PR, Morrison JH. Neurofibrillary tangle densities in the hippocampal formation in a non-demented population define subgroups of patients with differential early pathologic changes. Neurosci Lett . 1993; 153: 131–135.
9.
Bouras C, Hof PR, Giannakopoulos P, Michel JP, Morrison JH. Regional distribution of neurofibrillary tangles and senile plaques in the cerebral cortex of elderly patients: a quantitative evaluation of a one-year autopsy population from a geriatric hospital. Cereb Cortex . 1994; 4: 138–150.
10.
Bierer LM, Hof PR, Purohit D, et al. Neocortical neurofibrillary tangles correlate with dementia severity in Alzheimer’s disease. Arch Neurol . 1995; 52: 81–88.
11.
Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol . 1991; 82: 239–259.
12.
Crystal H, Dickson D, Fuld P, et al. Clinico-pathologic studies in dementia: nondemented subjects with pathologically confirmed Alzheimer’s disease. Neurology . 1988; 38: 1682–1687.
13.
Dickson DW, Crystal HA, Mattiace LA, et al. Identification of normal and pathological aging in prospectively studied nondemented elderly humans. Neurobiol Aging . 1991; 13: 179–189.
14.
Katzman R, Terry R, DeTeresa R, et al. Clinical, pathological, and neurochemical changes in dementia: a subgroup with preserved mental status and numerous neocortical plaques. Ann Neurol . 1988; 23: 138–144.
15.
Price JL, Davis PB, Morris JC, White DL. The distribution of tangles, plaques and related immunohistochemical markers in healthy aging and Alzheimer’s disease. Neurobiol Aging . 1991; 12: 295–312.
16.
Arriagada PV, Marzloff K, Hyman BT. Distribution of Alzheimer-type pathologic changes in nondemented elderly individuals matches the pattern in Alzheimer’s disease. Neurology . 1992; 42: 1681–1688.
17.
Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer’s disease. Neurology . 1992; 42: 631–639.
18.
Cummings BJ, Pike CJ, Shankle R, Cotman CW. Beta-amyloid deposition and other measures of neuropathology predict cognitive status in Alzheimer’s disease. Neurobiol Aging . 1996; 17: 921–933.
19.
Näslund J, Haroutunian V, Mohs R, et al. Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA . 2000; 283: 1571–1577.
20.
Bussière T, Friend PD, Sadeghi N, et al. Stereologic assessment of the total cortical volume occupied by amyloid deposits and its relationship with cognitive status in aging and Alzheimer’s disease. Neuroscience . 2002; 112: 75–91.
21.
Gómez-Isla T, Price JL, McKeel DW Jr, Morris JC, Growdon JH, Hyman BT. Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer’s disease. J Neurosci . 1996; 16: 4491–4500.
22.
Gómez-Isla T, Hollister R, West H, et al. Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer’s disease. Ann Neurol . 1997; 41: 17–24.
23.
West MJ, Gundersen HJG. Unbiased stereological estimation of the number of neurons in the human hippocampus. J Comp Neurol . 1990; 296: 1–22.
24.
West MJ. Regionally specific loss of neurons in the aging human hippocampus. Neurobiol Aging . 1993; 14: 287–293.
25.
West MJ, Coleman PD, Flood DG, Troncoso JC. Differences in the pattern of hippocampal neuronal loss in normal ageing and Alzheimer’s disease. Lancet . 1994; 344: 769–772.
26.
West MJ, Slomianka L. Total number of neurons in the layers of the human entorhinal cortex [published erratum in 1998;8: 426]. Hippocampus . 1998; 8: 69–82.
27.
Simic G, Kostovic I, Winblad B, Bodganovic N. Volume and number of neurons of the human hippocampal formation in normal aging and Alzheimer’s disease. J Comp Neurol . 1997; 379: 482–494.
28.
Harding AJ, Halliday GM, Kril JJ. Variation in hippocampal neuron number with age and brain volume. Cereb Cortex . 1998; 8: 710–718.
29.
Price JL, Ko AI, Wade MJ, Tsou SK, McKeel DW, Morris JC. Neuron number in the entorhinal cortex and CA1 in preclinical Alzheimer disease. Arch Neurol . 2001; 58: 1395–1402.
30.
Kril JJ, Patel S, Harding AJ, Halliday GM. Neuron loss from Alzheimer’s disease exceeds extracellular neurofibrillary tangle formation. Acta Neuropathol . 2002; 103: 370–376.
31.
Morsch R, Simon W, Coleman PD. Neurons may live for decades with neurofibrillary tangles. J Neuropathol Exp Neurol . 1999; 58: 188–197.
32.
Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res . 1975; 12: 189–198.
33.
Perl DP, Good PF, Bussière T, Morrison JH, Erwin JM, Hof PR. Practical approaches to stereology in the setting of aging- and disease-related brain banks. J Chem Neuroanat . 2000; 20: 7–19.
34.
Buée-Scherrer V, Condamines O, Mourton-Gilles C, et al. AD2, a phosphorylation-dependent monoclonal antibody directed against tau proteins found in Alzheimer’s disease. Mol Brain Res . 1996; 39: 79–88.
35.
Wisniewski HM, Wen GY, Kim KS. Comparison of four staining methods on the detection of neuritic plaques. Acta Neuropathol . 1989; 78: 22–27.
36.
Amaral DG, Insausti R. Hippocampal formation. In: Paxinos G, ed. The human nervous system. San Diego: Academic Press, 1990: 711–755.
37.
Hof PR, Nimchinsky EA, Young WG, Morrison JH. Numbers of Meynert and layer IVB cells in area V1: a stereologic analysis in young and aged macaque monkeys. J Comp Neurol . 2000; 420: 113–126.
38.
Kordower JH, Chu Y, Stebbins GT, et al. Loss and atrophy of layer II entorhinal cortex neurons in elderly people with mild cognitive impairment. Ann Neurol . 2001; 49: 202–213.
39.
Campbell MJ, Morrison JH. A monoclonal antibody to neurofilament protein (SMI-32) labels a subpopulation of pyramidal neurons in the human and monkey neocortex. J Comp Neurol . 1989; 282: 191–200.
40.
Hof PR, Mufson EJ, Morrison JH. The human orbitofrontal cortex: cytoarchitecture and quantitative immunohistochemical parcellation. J Comp Neurol . 1995; 359: 48–68.
41.
Terry RD, DeTeresa R, Hansen LA. Neocortical cell counts in normal human adult aging. Ann Neurol . 1987; 21: 530–539.
42.
Terry RD, Peck A, DeTeresa R, Schechter R, Horoupian DS. Some morphometric aspects of the brain in senile dementia of the Alzheimer’s type. Ann Neurol . 1981; 10: 184–192.
43.
Cras P, Smith MA, Richey PL, Siedlak SL, Mulvihill P, Perry G. Extracellular neurofibrillary tangles reflect neuronal loss and provide further evidence of extensive protein cross-linking in Alzheimer disease. Acta Neuropathol . 1995; 89: 291–295.
44.
Schwab C, Steele JC, McGeer PL. Pyramidal neuron loss is matched by ghost tangle increase in Guam parkinsonism-dementia hippocampus. Acta Neuropathol . 1998; 96: 409–416.
45.
Schwab C, Schulzer M, Steele JC, McGeer PL. On the survival time of a tangled neuron in the hippocampal CA4 region in parkinsonism-dementia complex of Guam. Neurobiol Aging . 1999; 20: 57–63.
46.
Gold G, Kövari E, Corte G, et al. Clinical validity of Aβ-protein deposition staging in brain aging and Alzheimer’s disease. J Neuropathol Exp Neurol . 2001; 60: 946–952.
47.
Grober E, Dickson D, Sliwinski MJ, et al. Memory and mental status correlates of modified Braak staging. Neurobiol Aging . 1999; 20: 573–579.
48.
Walsh DM, Klyubin I, Fadeeva JV, Rowan MJ, Selkoe DJ. Amyloid-beta oligomers: their production, toxicity and therapeutic inhibition. Biochem Soc Trans . 2002; 30: 552–557.
49.
Dickson DW, Crystal HA, Bevona C, Honer W, Vincent I, Davies P. Correlations of synaptic and pathological markers with cognition of the elderly. Neurobiol Aging . 1995; 16: 285–298.

Information & Authors

Information

Published In

Neurology®
Volume 60Number 9May 13, 2003
Pages: 1495-1500
PubMed: 12743238

Publication History

Received: September 6, 2002
Accepted: January 30, 2003
Published online: May 13, 2003
Published in print: May 13, 2003

Permissions

Request permissions for this article.

Authors

Affiliations & Disclosures

P. Giannakopoulos, MD
From the Departments of Psychiatry (Drs. Giannakopoulos, Bouras, and Kövari) and Geriatrics (Drs. Herrmann and Gold), HUG Belle-Idée, University of Geneva School of Medicine; Department of Psychogeriatrics (Dr. Giannakopoulos), University of Lausanne School of Medicine, Switzerland; Kastor Neurobiology of Aging Laboratories and Fishberg Research Center for Neurobiology (Drs. Bussière, Bouras, Perl, Morrison, and Hof) and Departments of Geriatrics and Adult Development (Drs. Morrison and Hof), Ophthalmology (Dr. Hof), Pathology (Dr. Perl), and Psychiatry (Dr. Perl), Mount Sinai School of Medicine, New York, NY; and Elan Pharmaceuticals Inc. (Dr. Bussière), South San Francisco, CA.
F. R. Herrmann, MD MPH
From the Departments of Psychiatry (Drs. Giannakopoulos, Bouras, and Kövari) and Geriatrics (Drs. Herrmann and Gold), HUG Belle-Idée, University of Geneva School of Medicine; Department of Psychogeriatrics (Dr. Giannakopoulos), University of Lausanne School of Medicine, Switzerland; Kastor Neurobiology of Aging Laboratories and Fishberg Research Center for Neurobiology (Drs. Bussière, Bouras, Perl, Morrison, and Hof) and Departments of Geriatrics and Adult Development (Drs. Morrison and Hof), Ophthalmology (Dr. Hof), Pathology (Dr. Perl), and Psychiatry (Dr. Perl), Mount Sinai School of Medicine, New York, NY; and Elan Pharmaceuticals Inc. (Dr. Bussière), South San Francisco, CA.
T. Bussière, PhD
From the Departments of Psychiatry (Drs. Giannakopoulos, Bouras, and Kövari) and Geriatrics (Drs. Herrmann and Gold), HUG Belle-Idée, University of Geneva School of Medicine; Department of Psychogeriatrics (Dr. Giannakopoulos), University of Lausanne School of Medicine, Switzerland; Kastor Neurobiology of Aging Laboratories and Fishberg Research Center for Neurobiology (Drs. Bussière, Bouras, Perl, Morrison, and Hof) and Departments of Geriatrics and Adult Development (Drs. Morrison and Hof), Ophthalmology (Dr. Hof), Pathology (Dr. Perl), and Psychiatry (Dr. Perl), Mount Sinai School of Medicine, New York, NY; and Elan Pharmaceuticals Inc. (Dr. Bussière), South San Francisco, CA.
C. Bouras, MD
From the Departments of Psychiatry (Drs. Giannakopoulos, Bouras, and Kövari) and Geriatrics (Drs. Herrmann and Gold), HUG Belle-Idée, University of Geneva School of Medicine; Department of Psychogeriatrics (Dr. Giannakopoulos), University of Lausanne School of Medicine, Switzerland; Kastor Neurobiology of Aging Laboratories and Fishberg Research Center for Neurobiology (Drs. Bussière, Bouras, Perl, Morrison, and Hof) and Departments of Geriatrics and Adult Development (Drs. Morrison and Hof), Ophthalmology (Dr. Hof), Pathology (Dr. Perl), and Psychiatry (Dr. Perl), Mount Sinai School of Medicine, New York, NY; and Elan Pharmaceuticals Inc. (Dr. Bussière), South San Francisco, CA.
E. Kövari, MD
From the Departments of Psychiatry (Drs. Giannakopoulos, Bouras, and Kövari) and Geriatrics (Drs. Herrmann and Gold), HUG Belle-Idée, University of Geneva School of Medicine; Department of Psychogeriatrics (Dr. Giannakopoulos), University of Lausanne School of Medicine, Switzerland; Kastor Neurobiology of Aging Laboratories and Fishberg Research Center for Neurobiology (Drs. Bussière, Bouras, Perl, Morrison, and Hof) and Departments of Geriatrics and Adult Development (Drs. Morrison and Hof), Ophthalmology (Dr. Hof), Pathology (Dr. Perl), and Psychiatry (Dr. Perl), Mount Sinai School of Medicine, New York, NY; and Elan Pharmaceuticals Inc. (Dr. Bussière), South San Francisco, CA.
D. P. Perl, MD
From the Departments of Psychiatry (Drs. Giannakopoulos, Bouras, and Kövari) and Geriatrics (Drs. Herrmann and Gold), HUG Belle-Idée, University of Geneva School of Medicine; Department of Psychogeriatrics (Dr. Giannakopoulos), University of Lausanne School of Medicine, Switzerland; Kastor Neurobiology of Aging Laboratories and Fishberg Research Center for Neurobiology (Drs. Bussière, Bouras, Perl, Morrison, and Hof) and Departments of Geriatrics and Adult Development (Drs. Morrison and Hof), Ophthalmology (Dr. Hof), Pathology (Dr. Perl), and Psychiatry (Dr. Perl), Mount Sinai School of Medicine, New York, NY; and Elan Pharmaceuticals Inc. (Dr. Bussière), South San Francisco, CA.
J. H. Morrison, PhD
From the Departments of Psychiatry (Drs. Giannakopoulos, Bouras, and Kövari) and Geriatrics (Drs. Herrmann and Gold), HUG Belle-Idée, University of Geneva School of Medicine; Department of Psychogeriatrics (Dr. Giannakopoulos), University of Lausanne School of Medicine, Switzerland; Kastor Neurobiology of Aging Laboratories and Fishberg Research Center for Neurobiology (Drs. Bussière, Bouras, Perl, Morrison, and Hof) and Departments of Geriatrics and Adult Development (Drs. Morrison and Hof), Ophthalmology (Dr. Hof), Pathology (Dr. Perl), and Psychiatry (Dr. Perl), Mount Sinai School of Medicine, New York, NY; and Elan Pharmaceuticals Inc. (Dr. Bussière), South San Francisco, CA.
G. Gold, MD
From the Departments of Psychiatry (Drs. Giannakopoulos, Bouras, and Kövari) and Geriatrics (Drs. Herrmann and Gold), HUG Belle-Idée, University of Geneva School of Medicine; Department of Psychogeriatrics (Dr. Giannakopoulos), University of Lausanne School of Medicine, Switzerland; Kastor Neurobiology of Aging Laboratories and Fishberg Research Center for Neurobiology (Drs. Bussière, Bouras, Perl, Morrison, and Hof) and Departments of Geriatrics and Adult Development (Drs. Morrison and Hof), Ophthalmology (Dr. Hof), Pathology (Dr. Perl), and Psychiatry (Dr. Perl), Mount Sinai School of Medicine, New York, NY; and Elan Pharmaceuticals Inc. (Dr. Bussière), South San Francisco, CA.
P. R. Hof, MD
From the Departments of Psychiatry (Drs. Giannakopoulos, Bouras, and Kövari) and Geriatrics (Drs. Herrmann and Gold), HUG Belle-Idée, University of Geneva School of Medicine; Department of Psychogeriatrics (Dr. Giannakopoulos), University of Lausanne School of Medicine, Switzerland; Kastor Neurobiology of Aging Laboratories and Fishberg Research Center for Neurobiology (Drs. Bussière, Bouras, Perl, Morrison, and Hof) and Departments of Geriatrics and Adult Development (Drs. Morrison and Hof), Ophthalmology (Dr. Hof), Pathology (Dr. Perl), and Psychiatry (Dr. Perl), Mount Sinai School of Medicine, New York, NY; and Elan Pharmaceuticals Inc. (Dr. Bussière), South San Francisco, CA.

Notes

Address correspondence and reprint requests to Prof. Panteleimon Giannakopoulos, Clinic of Geriatric Psychiatry, Department of Psychiatry, University of Geneva School of Medicine, 1225 Chêne-Bourg, Geneva, Switzerland; e-mail: [email protected]

Metrics & Citations

Metrics

Citations

Download Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.

Cited By
  1. Rodent Models of Alzheimer’s Disease: Past Misconceptions and Future Prospects, International Journal of Molecular Sciences, 25, 11, (6222), (2024).https://doi.org/10.3390/ijms25116222
    Crossref
  2. The “Hit and Run” Hypothesis for Alzheimer’s Disease Pathogenesis, International Journal of Molecular Sciences, 25, 6, (3245), (2024).https://doi.org/10.3390/ijms25063245
    Crossref
  3. Tyrosine kinases: multifaceted receptors at the intersection of several neurodegenerative disease-associated processes, Frontiers in Dementia, 3, (2024).https://doi.org/10.3389/frdem.2024.1458038
    Crossref
  4. Cerebrospinal fluid level of proNGF as potential diagnostic biomarker in patients with frontotemporal dementia, Frontiers in Aging Neuroscience, 15, (2024).https://doi.org/10.3389/fnagi.2023.1298307
    Crossref
  5. Early CA2 Tau Inclusions Do Not Distinguish an Age-Related Tauopathy from Early Alzheimer’s Disease, Journal of Alzheimer's Disease, 101, 4, (1333-1353), (2024).https://doi.org/10.3233/JAD-240483
    Crossref
  6. Substantial Doubt Remains about the Efficacy of Anti-Amyloid Antibodies, Journal of Alzheimer's Disease, 97, 2, (567-572), (2024).https://doi.org/10.3233/JAD-231198
    Crossref
  7. APOER2 splicing repertoire in Alzheimer’s disease: Insights from long-read RNA sequencing, PLOS Genetics, 20, 7, (e1011348), (2024).https://doi.org/10.1371/journal.pgen.1011348
    Crossref
  8. Targeting vulnerable microcircuits in the ventral hippocampus of male transgenic mice to rescue Alzheimer-like social memory loss, Military Medical Research, 11, 1, (2024).https://doi.org/10.1186/s40779-024-00512-z
    Crossref
  9. Aqueous extractable nonfibrillar and sarkosyl extractable fibrillar Alzheimer’s disease tau seeds have distinct properties, Acta Neuropathologica Communications, 12, 1, (2024).https://doi.org/10.1186/s40478-024-01849-1
    Crossref
  10. Tau in neurodegenerative diseases: molecular mechanisms, biomarkers, and therapeutic strategies, Translational Neurodegeneration, 13, 1, (2024).https://doi.org/10.1186/s40035-024-00429-6
    Crossref
  11. See more
Loading...

View Options

Login options

Check if you have access through your login credentials or your institution to get full access on this article.

Personal login Institutional Login
Purchase Options

The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.

If you need immediate support or to place an order, please call or email customer service:

  • 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
  • 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
  • [email protected]

We appreciate your patience during this time and apologize for any inconvenience.

View options

PDF and All Supplements

Download PDF and Supplementary Material

Full Text

View Full Text

Full Text HTML

View Full Text HTML

Media

Figures

Other

Tables

Share

Share

Share article link

Share